LYON, France, September 22, 2022 — EDAP TMS S.A. (NASDAQ: EDAP) (the “Firm”), a worldwide chief in robotic energy-based therapies, introduced that the value of its public providing of its American Depositary Shares (“ADSs”), which commenced on September 22, 2022, has been set in the present day at $7.50 per ADS, earlier than underwriting reductions and commissions, and that the variety of provided ADSs is 2,666,667. As well as, Jefferies LLC has been granted a 30-day over-allotment choice to buy as much as a further 400,000 ADSs on the identical phrases and situations. The gross proceeds from the providing, earlier than deducting underwriting reductions and commissions and different providing bills payable by the Firm, are anticipated to be roughly $20,000,003. The closing of the providing today techs is predicted to happen on September 27, 2022, topic to customary closing situations.
Jefferies LLC is performing as the only real book-running supervisor today techs for the providing.
A shelf registration assertion on Kind F-3 (together with a prospectus) referring to the Firm’s American Depositary Shares was filed with the Securities and Change Fee (the “SEC”) on April 7, 2021 and is efficient. The Firm has additionally filed a base prospectus dated April 16, 2021 and a preliminary prospectus complement dated September 22, 2022 with respect to the providing. A closing prospectus complement and the accompanying prospectus can be filed with the SEC. It’s possible you’ll receive these paperwork totally free by visiting EDGAR on the SEC’s web site at www.sec.gov. Alternatively, when obtainable, a duplicate of the prospectus complement (and accompanying prospectus) referring to the providing could also be obtained from Jefferies LLC, Attn: Fairness Syndicate Prospectus Division, 520 Madison Avenue, 2nd Flooring, New York, New York 10022, by phone at +1 (877) 821-7388 or by e-mail at Prospectus_Department@Jefferies.com.
This press launch shall not represent a proposal to promote or the today techs solicitation of a proposal to purchase these securities, nor shall there be any sale of those securities in any state or jurisdiction wherein such supply, solicitation or sale could be illegal previous to registration or qualification underneath the securities legal guidelines of any such state or jurisdiction. Specifically, no public providing of the ADSs can be made in Europe.
This press launch comprises forward-looking statements throughout the that means of the Non-public Securities Litigation Reform Act of 1995, together with statements concerning the anticipated closing of the Firm’s follow-on providing. Such statements are based mostly on administration’s present expectations and are topic to quite a few dangers and uncertainties, together with issues not but today techs identified to us or not at the moment thought-about materials by us, and there may be no assurance that anticipated occasions will happen or that the targets set out will really be achieved. Essential elements that would trigger precise outcomes to vary materially from the outcomes anticipated within the forward-looking statements embrace, however are usually not restricted to, uncertainties associated to market situations, satisfaction of the closing situations of the providing, these dangers referring to the providing and others described within the preliminary prospectus complement and particularly within the sections “Ahead-Wanting Info” and “Threat Components” and people dangers referring to today techs the Firm’s enterprise, that are described within the Firm’s filings with the SEC and particularly within the part “Threat Components” within the Firm’s Annual Report on Kind 20-F. The Firm undertakes no obligation to replace or revise any forward-looking statements with a purpose to replicate any occasion or circumstance that will come up after the date of this launch, besides as required by legislation.
Investor Relations / Authorized Affairs
EDAP TMS SA
+33 4 72 15 31 50
LifeSci Advisors, LLC